Develops and manufactures branded and generic prescription pharmaceuticals. Focuses on controlled substances, oncology products, hormones, and injectables. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 42% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $39.6M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 20.4× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 86% of them.
Analysts' average target sits 49% above today's price.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 42% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, executives reported 86 sells against just 18 buys. Not an alarm bell by itself, but a number worth watching.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, ANIP sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ANIP is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.